As reported by The Pharma Letter, the biotechnology company Amgen have teamed up with the US generic drug maker Watson Pharmaceuticals in order to develop and commercialise oncology antibody biosimilar medicines.
Amgen will be responsible for the development, manufacturing and commercialising the oncology antibody products, whilst Watson will contribute $400m across the course of project. Watson will also provide their expertise in marketing the products in more competitive and generic markets. They will also be instrumental in managing the lifecycle of the biosimilar products.
Speaking of the announcement, Robert Bradway, president and CEO at Amgen stated, “The pairing of Amgen’s 30 years of experience in biologics together with Watson’s substantial generics and specialty pharmaceutical experience and complementary commercial and distribution capabilities provides great potential for worldwide patient access to high quality oncology biosimilar medicines.”
This type of activity seems to be becoming more and more common. In fact, earlier this month Biogen collaborated with Samsung and established a join venture to do just this. In addition, many other large pharmaceutical companies are planning to embark on this, including Merck & Co, Novartis and Pfizer.